WeedStreet420
  • Newsletter
  • Colors
    Light Theme Dark Theme
    Screen options
    Full Screen Mode Boxed Layout Mode
    • Watch List
      • Daily Top Gainers
      • Daily Top Losers
      • 52-Weeks Highs
      • Most Volume
    • Psychedelics Companies List
    • TOP PICKS
    • Press Releases
    • News
      • All News
      • Shroom Stocks News
      • Science & Studies
      • Legislation News
    • Heat Map
    • Calendar
  • Watch List
    • Daily Top Gainers
    • Daily Top Losers
    • 52-Weeks Highs
    • Most Volume
  • Psychedelics Companies List
  • TOP PICKS
  • Press Releases
  • News
    • All News
    • Shroom Stocks News
    • Science & Studies
    • Legislation News
  • Heat Map
  • Calendar
WeedStreet420

SUBSCRIBE NOW

Join our subscribers!

By subscribing, you agree to our Terms and Conditions
We don't spam and we promise to never share your information.

944 views6 min read

Primo Nutraceuticals Inc., Engages MedCan Biotechnologies to Conduct Chemo typing & Geno-typing Studies of Psilocybin Mushrooms

Primo NutraceuticalsOctober 14, 2020 -

VANCOUVER, British Columbia, Oct. 14, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“PRIMO“)

Primo Nutraceuticals Inc. has entered intoa non-binding letter of intent (the “LOI”) with MedCanBiotechnologies Inc. (“MEDCAN BIOTECH”). MEDCAN BIOTECH will act as a consultant to conduct a chemo typing (Chemical Analysis) and a genotyping (Genetic Analysis) study of up to 5 strains of Psilocybin mushrooms (commonly known as Magic Mushrooms).


  Subscribe to news from
Primo Nutraceuticals

Be the first to know when breaking news are released.



Terms of Engagement

Health Canada (HC) has recently shifted towards psychedelic-assisted psychotherapies in safe, controlled environments as acceptable treatment options.

Pursuant to Section 56 exemption from the Canadian Drugs and Substances Act to treat anxiety associated diagnoses,MEDCAN BIOTECH will apply to Health Canada to receive approval under the Controlled Drug and Substances Act to allow MEDCAN BIOTECH to conduct research in order to effectively standardize the extraction of psilocybin from mushrooms.

The Health Canada permitby MEDCAN BIOTECHwill allow to develop and license intellectual property (IP) exclusively for further product development by PRIMO via chemo-typing and geno-typing of 5 different mushrooms to understand their properties.

MEDCAN BIOTECHwill proceedto patent methods of analysis and results on behalf of PRIMO, whereby data generated will be used in the production of nutraceutical products.

All IPand products developed as a result of the analysis will become the property of PRIMOfor their exclusive use.

Psychedelic research focused on psychedelic medicine and psychedelic drugs have demonstrated that these substances have potential for treating ailments including anxiety, addiction, depression, substance dependency, attention deficit hyperactivity disorder and even post-traumatic stress disorder.The data produced can be used to generate premium natural health mushroom nutraceutical products. Genotyping can be used for the identification and labeling of different varieties of psilocybin mushrooms.

About MEDCAN BIOTECH

MEDCAN BIOTECH is an all-natural solution research and development company to better personal wellbeing.MEDCAN BIOTECH has already researched and formulated a range of cannabinoid products that combine with the multi-faceted cannabinoid component with other natural active ingredients to create products for Sleep, Mood, Mind and Pleasure presented online at: www.medcanbiotech.com

Founder, Dr. David Noshad is a part-time faculty member at British Columbia’s Thompson Rivers University as well as President of Bio-Act Technology which specializes in research and development consulting with respects to life-science, cannabis and agri-food industry.

In 2010, Dr. Noshad served as Principle Co-Investigator with the UBC’s Faculty of Pharmaceutical Sciences in cannabis pharmacology; characterizing cannabinoids and terpenes in cannabis and Humulus. The projects included in vitro culture techniques, biochemical analysis, molecular biology and genomic techniques.

About the Psychedelic Market

In the first half of 2020, US$150 million was raised by psychedelics-focused companies. The research group projects that the global psychedelics industry may reach a total value of US$7 billion by the year 2027. According to: https://reportonpsychedelics.com/

Richard Cindric, CEO of Primo Comments:

“It is an honor to have Dr. Noshad collaborating with us. We are confident his qualifications and experience in characterizing cannabinoids and terpenes in cannabis will translate into the development of IP focusing on psilocybin treatments for neuropsychiatric diseases.

By investing resources in functional mushroom beverages with Brujera Elixer, as well as developing an IP on psychedelics with MedCan, we will be able to introduce premium natural health mushroom products toboth thepsychedelic and non-psychedelic market places.”

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo Nutra’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License(MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

“AndyJagpal”

Andy Jagpal
President and Director

For further information, please contact Zoltan Sarkozy, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net
www.statebelevate.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

  • Share on Twitter
  • Facebook
  • Reddit
  • LinkedIn

BUGVFPrimo Nutraceuticals Inc.PRMOPRMO.CN





More news from Primo Nutraceuticals

  • Marianna Naturals Corp. Announces It Has Been Approved as a Walmart Marketplace Seller

    Primo NutraceuticalsDecember 11, 2020 -
  • Agritek Holdings Inc. Announces Executed Asset Purchase Agreement For Acquisition Of Full Spectrum Biosciences By Canada Based Primo Nutraceuticals Inc. Trading On CSE and OTC Exchanges

    Primo NutraceuticalsNovember 12, 2020 -
  • Primo Nutraceuticals Inc. Enters intoa Binding LOI to acquire 100% of the Assets of Full Spectrum Biosciences Inc.

    Primo NutraceuticalsNovember 12, 2020 -
  • Marianna Naturals Corp. Appoints Integral Transfer Agency as its Transfer Agent, and Secures Its CUSIP & ISIN

    Primo NutraceuticalsOctober 26, 2020 -
  • Primo Nutraceuticals Inc. signs a Memorandum of Understanding for Exclusive Rights to Sell Rapid (Colloidal Gold Method) COVID-19 Test Kits in Canada

    Primo NutraceuticalsOctober 21, 2020 -
  • Primo Nutraceuticals Inc. Signs Letter of Intent with Brujera Elixirs Inc. to Formulate 4 Innovative Adaptogenic Mushroom-Infused Beverage Products

    Primo NutraceuticalsOctober 1, 2020 -

View Watch List (65 companies)

POPULAR

Silo Pharma Expands License Agreement and Patent Portfolio

857 Views

Numinus Unveils New Logo and Brand Identity

852 Views

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st Annual Mental Healthcare Conference on June 27, 2022

434 Views

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

93 Views

Field Trip Health Ltd. Announces Voting Results From Special Shareholder Meeting

93 Views

Pure Extracts Receives Purchase Order for a New Listing of High-Potency Vape Carts from the Ontario Cannabis Store

88 Views

BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference

58 Views

Delic Corp to Present Vision for Long-Term Growth and Industry-Leading Clinic Developments at First Annual H.C. Wainwright Mental Health Conference

57 Views

Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA

5 Views

Red Light Holland Update Plans to Enter Oregon Legal Psilocybin Service Market to Promote Diversity and Equity in Alignment with Measure 109 Regulations

5 Views

RECENT

Field Trip Health Ltd. Receives Final Court Approval for Reorganization of the Discovery and Wellness Businesses Into Two Publicly Traded Companies

0 Views

Red Light Holland Update Plans to Enter Oregon Legal Psilocybin Service Market to Promote Diversity and Equity in Alignment with Measure 109 Regulations

0 Views

Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA

0 Views

Pure Extracts Receives Purchase Order for a New Listing of High-Potency Vape Carts from the Ontario Cannabis Store

0 Views

Field Trip Health Ltd. Announces Voting Results From Special Shareholder Meeting

0 Views

Numinus Unveils New Logo and Brand Identity

0 Views

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

0 Views

Silo Pharma Expands License Agreement and Patent Portfolio

0 Views

Delic Corp to Present Vision for Long-Term Growth and Industry-Leading Clinic Developments at First Annual H.C. Wainwright Mental Health Conference

0 Views

BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference

0 Views





Make smarter investment strategies
with in-depth news reports

Join our subscribers!

By subscribing, you agree to our Terms and Conditions
We don't spam and we promise to never share your information.

Risk Warning
Privacy Policy
Methodology
Disclaimer
Contact Us
Advertising
© 2022 Shroom Investor 🍄 is a subsidiary of Upside Makers inc.   By using this website, you agree to our Terms of Use